

Marcin Dada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10910979/publications.pdf>

Version: 2024-02-01

27
papers

7,080
citations

411340

20
h-index

591227

27
g-index

27
all docs

27
docs citations

27
times ranked

5866
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 2020, 130, 1-6.	0.7	2
2	Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial). American Journal of Cardiology, 2015, 116, 167-173.	0.7	15
3	Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. New England Journal of Medicine, 2015, 373, 1937-1946.	13.9	225
4	Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	1.1	178
5	Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 409-418.	0.9	30
6	Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: Assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial. American Heart Journal, 2013, 166, 481-487.	1.2	28
7	Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients. Journal of the American College of Cardiology, 2013, 62, 1826-1833.	1.2	84
8	Health Status and Quality of Life in Patients With Stable Coronary Artery Disease and Chronic Kidney Disease Treated With Optimal Medical Therapy or Percutaneous Coronary Intervention (Post Hoc) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	178
9	Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. American Heart Journal, 2012, 164, 243-250.	1.2	175
10	Effectiveness of Percutaneous Coronary Intervention in Patients With Silent Myocardial Ischemia (Post Hoc Analysis of the COURAGE Trial). American Journal of Cardiology, 2012, 109, 954-959.	0.7	20
11	Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive) Tj ETQq1 1 0.784314 44 BT /Overl	0.784314	44
12	Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy. Circulation: Cardiovascular Interventions, 2011, 4, 545-552.	1.4	49
13	The Cost-Effectiveness of Percutaneous Coronary Intervention as a Function of Angina Severity in Patients With Stable Angina. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 172-182.	0.9	20
14	Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System?. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 476-483.	0.9	6
15	Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1348-1358.	1.2	96
16	Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 320-327.	0.9	37
17	Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the) Tj ETQq1 1 0.784314 44 BT /Overl	0.784314	44
18	Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. American Journal of Cardiology, 2009, 104, 1055-1062.	0.7	43

#	ARTICLE	IF	CITATIONS
19	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2009, 104, 1647-1653.	0.7	94
20	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1303-1308.	1.2	54
21	Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 12-20.	0.9	114
22	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden. <i>Circulation</i> , 2008, 117, 1283-1291.	1.6	1,478
23	Response to Letters Regarding Article, "Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy": <i>Circulation</i> , 2008, 118,...	1.6	1
24	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 1503-1516.	13.9	4,022
25	The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. <i>American Journal of Cardiology</i> , 2007, 99, 208-212.	0.7	70
26	Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. <i>American Heart Journal</i> , 2006, 151, 1173-1179.	1.2	82
27	Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 685-698.	1.4	34